|
PharmaEngine, Inc. is a biotechnology company operating under a virtual pharmaceutical company business model. The company focuses on precision cancer therapy, with research areas including DNA damage response and synthetic lethality targets. Its lead product, ONIVYDE, is a microsome formulation of a topoisomerase I inhibitor developed using nanotechnology to treat cancer. The company is also developing PEP08, a new drug candidate currently undergoing Phase I clinical trials for solid tumors. PharmaEngine serves the oncology market, with ONIVYDE approved for use in first-line combination therapy for metastatic pancreatic cancer. Summarised from the company's own disclosures |
Industry Biotechnology | Homepage pharmaengine.com |
| Sector Healthcare | IR page pharmaengine.com/investors | |
|
Tags
oncology, nanotechnology, topoisomerase inhibitors, precision medicine, clinical trials, pancreatic cancer, ONIVYDE, PEP08
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 7.241B |
| Market cap (USD) | $ 219.771M |
| P/E | 13.33 |
| PEG | 1.98 |
| P/BV | 1.43 |
| P/S | 6.89 |
| P/OCF | 15.85 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.5% |
| ROI | 7.9% |
| ROIC | 6.6% |
| Profit margin | 42.5% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 6.7% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -18.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 911.416M | 2.523B | 767.669M | 654.383M | 654.835M | 1.056B | 314.04M | 293.43M | 853.677M | 1.135B | 507.244M | 228.986M | 37.4M |
| Net profit | 387.641M | 1.751B | 274.65M | 318.783M | 426.031M | 604.281M | 42.55M | 129.362M | 387.063M | 689.625M | 394.022M | 123.592M | -117.848M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 70.4 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/S | 11.1 | — | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding PharmaEngine, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 10,000 | $ 15.991K | Nov 16, 2026 |
| DFEV | 0.00% | 47,000 | $ 75.555K | Nov 12, 2026 |
| DFSE | 0.00% | 11,000 | $ 17.683K | Nov 12, 2026 |
| DFEM | 0.00% | 121,000 | $ 194.513K | Nov 12, 2026 |
| DFAE | 0.00% | 77,000 | $ 123.781K | Nov 12, 2026 |
| DFAX | 0.00% | 68,000 | $ 109.313K | Nov 12, 2026 |
| AVEM | 0.00% | 65,000 | $ 103.942K | Nov 16, 2026 |
| AVES | 0.00% | 2,000 | $ 3,198.20 | Nov 16, 2026 |
| AVXC | 0.00% | 5,000 | $ 7,995.51 | Nov 16, 2026 |